On 14 May, China approved the inactivated virus vaccine developed by Minhai Biotechnology Co, a biotechnology company based in Pekin. This type of vaccine uses a dead version of the virus that causes the disease, unable to infect but capable of generating an immune response.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.